Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016179096> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2016179096 endingPage "9" @default.
- W2016179096 startingPage "3" @default.
- W2016179096 abstract "The aim of the study was to analyze the benefit/toxicity profile of a second-line treatment with carboplatin alone or carboplatin plus another non-cross-resistant drug (epidoxorubicin) in ovarian cancer patients sensitive to cisplatin-based chemotherapy at first-line treatment.We conducted a randomized clinical trial. Women with epithelial ovarian cancer FIGO Stage II--IV who had a complete or partial response to first-line treatment with cisplatin or carboplatin-based regiments and subsequently progressed or relapsed more than 6 months after discontinuation of first-line treatment were eligible for the study. A total of 190 subjects entered the study. They were randomly allocated to either 300 mg/m(2) of carboplatin every 28 days for five cycles (95 patients) or 120 mg/m(2) of epidoxorubicin and 300 mg/m(2) of carboplatin every 28 days for five cycles (95 patients).A complete response was reported, respectively, in 32 (36%) women allocated to carboplatin alone and in 28 (31.8%) of those allocated to carboplatin plus epidoxorubicin. The corresponding figures for partial response were 18 (20.2%) and 26 (29.9%). Comparing the frequency of complete response, partial response, no change, and progression, the differences between the two groups were not significant (chi(2)(3) 5.10, P = 0.16). The median duration of response was 16 months in the carboplatin alone and 20 months in the carboplatin plus epidoxorubicin group (P = not significant). The 3-year percentage of survival was 29% in the carboplatin alone and 42% in the carboplatin plus epidoxorubicin group; this difference was not statistically significant. The frequency of leukopenia, anemia, and thrombocytopenia grade 3-4 was higher in the epidoxorubicin plus carboplatin than in the carboplatin alone group. Alopecia G3 was present in 88% of women treated with epidoxorubicin plus carboplatin.The general results of this study do not show any marked differences in response to second-line treatment among women treated with single-agent (carboplatin) or multiagent (carboplatin plus epidoxorubicin) schedules. Toxicity, particularly hematological, was more relevant in women treated with the multiagent schedule." @default.
- W2016179096 created "2016-06-24" @default.
- W2016179096 creator A5002158178 @default.
- W2016179096 creator A5011235818 @default.
- W2016179096 creator A5011762682 @default.
- W2016179096 creator A5031438939 @default.
- W2016179096 creator A5042255432 @default.
- W2016179096 creator A5046199103 @default.
- W2016179096 creator A5048503259 @default.
- W2016179096 creator A5052040098 @default.
- W2016179096 creator A5062217195 @default.
- W2016179096 creator A5079315904 @default.
- W2016179096 date "2001-04-01" @default.
- W2016179096 modified "2023-10-16" @default.
- W2016179096 title "Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer" @default.
- W2016179096 cites W1892622076 @default.
- W2016179096 cites W1996131136 @default.
- W2016179096 cites W2038252730 @default.
- W2016179096 cites W2041960461 @default.
- W2016179096 cites W2063953472 @default.
- W2016179096 cites W2071363801 @default.
- W2016179096 cites W2117729836 @default.
- W2016179096 cites W2167805334 @default.
- W2016179096 cites W2245111413 @default.
- W2016179096 cites W2260361758 @default.
- W2016179096 cites W4243605909 @default.
- W2016179096 cites W4244837621 @default.
- W2016179096 doi "https://doi.org/10.1006/gyno.2001.6151" @default.
- W2016179096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11277642" @default.
- W2016179096 hasPublicationYear "2001" @default.
- W2016179096 type Work @default.
- W2016179096 sameAs 2016179096 @default.
- W2016179096 citedByCount "84" @default.
- W2016179096 countsByYear W20161790962012 @default.
- W2016179096 countsByYear W20161790962013 @default.
- W2016179096 countsByYear W20161790962014 @default.
- W2016179096 countsByYear W20161790962016 @default.
- W2016179096 countsByYear W20161790962017 @default.
- W2016179096 countsByYear W20161790962018 @default.
- W2016179096 countsByYear W20161790962019 @default.
- W2016179096 countsByYear W20161790962020 @default.
- W2016179096 countsByYear W20161790962021 @default.
- W2016179096 countsByYear W20161790962022 @default.
- W2016179096 crossrefType "journal-article" @default.
- W2016179096 hasAuthorship W2016179096A5002158178 @default.
- W2016179096 hasAuthorship W2016179096A5011235818 @default.
- W2016179096 hasAuthorship W2016179096A5011762682 @default.
- W2016179096 hasAuthorship W2016179096A5031438939 @default.
- W2016179096 hasAuthorship W2016179096A5042255432 @default.
- W2016179096 hasAuthorship W2016179096A5046199103 @default.
- W2016179096 hasAuthorship W2016179096A5048503259 @default.
- W2016179096 hasAuthorship W2016179096A5052040098 @default.
- W2016179096 hasAuthorship W2016179096A5062217195 @default.
- W2016179096 hasAuthorship W2016179096A5079315904 @default.
- W2016179096 hasConcept C121608353 @default.
- W2016179096 hasConcept C126322002 @default.
- W2016179096 hasConcept C126894567 @default.
- W2016179096 hasConcept C143998085 @default.
- W2016179096 hasConcept C2776694085 @default.
- W2016179096 hasConcept C2778239845 @default.
- W2016179096 hasConcept C2778715236 @default.
- W2016179096 hasConcept C2780427987 @default.
- W2016179096 hasConcept C2781451048 @default.
- W2016179096 hasConcept C71924100 @default.
- W2016179096 hasConceptScore W2016179096C121608353 @default.
- W2016179096 hasConceptScore W2016179096C126322002 @default.
- W2016179096 hasConceptScore W2016179096C126894567 @default.
- W2016179096 hasConceptScore W2016179096C143998085 @default.
- W2016179096 hasConceptScore W2016179096C2776694085 @default.
- W2016179096 hasConceptScore W2016179096C2778239845 @default.
- W2016179096 hasConceptScore W2016179096C2778715236 @default.
- W2016179096 hasConceptScore W2016179096C2780427987 @default.
- W2016179096 hasConceptScore W2016179096C2781451048 @default.
- W2016179096 hasConceptScore W2016179096C71924100 @default.
- W2016179096 hasIssue "1" @default.
- W2016179096 hasLocation W20161790961 @default.
- W2016179096 hasLocation W20161790962 @default.
- W2016179096 hasOpenAccess W2016179096 @default.
- W2016179096 hasPrimaryLocation W20161790961 @default.
- W2016179096 hasRelatedWork W1967715255 @default.
- W2016179096 hasRelatedWork W196860179 @default.
- W2016179096 hasRelatedWork W2080529225 @default.
- W2016179096 hasRelatedWork W2085363994 @default.
- W2016179096 hasRelatedWork W2154765149 @default.
- W2016179096 hasRelatedWork W2280856801 @default.
- W2016179096 hasRelatedWork W2419075599 @default.
- W2016179096 hasRelatedWork W2463572748 @default.
- W2016179096 hasRelatedWork W3047309708 @default.
- W2016179096 hasRelatedWork W5763337 @default.
- W2016179096 hasVolume "81" @default.
- W2016179096 isParatext "false" @default.
- W2016179096 isRetracted "false" @default.
- W2016179096 magId "2016179096" @default.
- W2016179096 workType "article" @default.